



RGC

PTO

21 MAR 2003

10/528645
PCT/GB 2003/5004026

INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 28 OCT 2003


WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated

16 October 2003

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

An Executive Agency of the Department of Trade and Industry

Patents Form 1/77

Patents Act 1977
(Rule 16)

THE PATENT OFFICE

27 SEP 2002

27SEP02 E751450-1 00302
P01/7700 0.00-0222426.9

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference

PZ0274

2. Patent application number

(The number)

0222426.9

27 SEP 2002

Name of the or of
applicant (underline all surnames)

IMAGING RESEARCH SOLUTIONS LIMITED

Cyclotron Building
Hammersmith Campus
DuCane Road
London
W12 0NN

Patents ADP number (if you know it)

If the applicant is a corporate body, give the
country/state of its incorporation

United Kingdom

8177883002

4. Title of the invention

CHEMICAL PROCESS

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom
to which all correspondence should be sent
(including the postcode)HAMMETT, Audrey, Grace, Campbell; ROLLINS, Anthony, John and
HAMMER, Catriona, MacLeod
Amersham plc
The Grove Centre
White Lion Road
Amersham
Buckinghamshire HP7 9LL

Patents ADP number (if you know it)

8189375002

6. If you are declaring priority from one or more
earlier patent applications, give the country
and the date of filing of the or of each of these
earlier applications and (if you know it) the or
each application number

Country

Priority application number
(if you know it)Date of filing
(day / month / year)7. If this application is divided or otherwise
derived from an earlier UK application,
give the number and the filing date of
the earlier application

Number of earlier application

Date of filing
(day / month / year)8. Is a statement of inventorship and of right
to grant of a patent required in support of
this request? (Answer 'Yes' if:

Yes

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

0048354 27-Sep-02 11:58

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 9

Claim(s) 5

Abstract 0

Drawing(s) 0

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77) 1

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

HAMMETT, Audrey, Grace, Campbell

We request the grant of a patent on the basis of this application

Signature

Date

25 September 2002

12. Name and daytime telephone number of person to contact in the United Kingdom LIVINGSTONE, Helen
01494 543390

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 50056
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Patents Form 1

CHEMICAL PROCESS

The present invention relates to a process for the preparation of fluorohaloalkane compounds such as [^{18}F]bromofluoromethane. [^{18}F]Fluorohaloalkanes are important reagents for performing O-, N-, and S- ^{18}F fluoroalkylations and are commonly used to radiolabel radioligands for use in positron emission tomography (PET) studies.

[^{18}F]Fluorohaloalkanes have previously been prepared by nucleophilic displacement, by [^{18}F]F $^-$, of a leaving group from a suitable precursor compound.


Thus, for example Zhang *et al*, Applied Radiation and Isotopes **57**, 335-342 (2002), describes synthesis of [^{18}F]fluoroethyl bromide by nucleophilic displacement of 2-trifluoromethanesulphonyloxy ethylbromide with [^{18}F]F $^-$ and Seung-Jun *et al* Applied Radiation and Isotopes (1999), **51**, 293-7 describes an analogous synthesis of 3- ^{18}F fluoropropylbromide. A similar method is described in Comagic *et al* Applied Radiation and Isotopes (2002), **56**, 847-851 wherein 2-bromo-1- ^{18}F fluoroethane is prepared by nucleophilic displacement of 1,2-dibromoethane with [^{18}F]F $^-$.

In view of the importance of [^{18}F]Fluorohaloalkanes as radiolabelling reagents, there exists the need for synthetic methods for their preparation in good radiochemical yield and in which isolation of the product is more readily achievable. Furthermore, there is also a need for such synthetic methods which are amenable to automation.


Therefore, according to the present invention, there is provided a process for preparation of a fluorohaloalkane of formula (I)



wherein X is halo and n is an integer of from 1 to 6; which comprises:
reaction of the corresponding organosilicon compound of formula (II):



10 wherein n is as defined for the compound of formula (I); and
R', R'', and R''' are independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl; and
R'' may alternatively be the group:




with a compound of formula (III):




wherein X is as defined for the compound of formula (I) and Y is halo.


20 In a preferred aspect of the invention, the fluorohaloalkane of formula (I) is a
[¹⁸F]fluorohaloalkane. Therefore, according to a further aspect of the present
invention, there is provided a process for preparation of a [¹⁸F]fluorohaloalkane of
formula (Ia)



wherein X is halo and n is an integer of from 1 to 6; which comprises:
reaction of the corresponding organosilicon compound of formula (IIa):



wherein n is as defined for the compound of formula (Ia); and
R', R'', and R''' are independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl; and
R'' may alternatively be the group:



with a compound of formula (III):



10 wherein X is as defined for the compound of formula (Ia) and Y is halo.

Examples of formula (I) which may be prepared using the present process, include
fluorobromomethane, fluoroiodomethane, fluorobromoethane, fluoroiodoethane,
fluorobromopropane, and fluoroiodopropane, each of which is suitably prepared
15 in [¹⁸F]-labelled form.

The reaction of a compound of formula (II) or (IIa) with a compound of formula (III)
may be performed in the presence of a catalyst, suitably a tetra (C₁₋₆ alkyl)
ammonium salt, such as a tetra (C₁₋₆ alkyl) ammonium fluoride salt, for example
20 tetrabutylammonium fluoride or tetraethylammonium fluoride; and in a suitable
solvent for example acetonitrile or an alcohol such as methanol or ethanol at
elevated temperature, for example 50°C to 150°C, suitably 70°C to 120°C.

The resulting compound of formula (I) or (Ia) may be isolated from the reaction
25 mixture, for example, by distillation followed by chromatography, suitably gas or
liquid chromatography. In a preferred isolation method, the crude reaction mixture
is distilled and the distillate is then passed under a stream of inert gas, such as
helium, through a temperature controlled GC column packed with silica gel.

30 The resulting compound of formula (I) or (Ia) may also be converted to a

corresponding fluoroalkylsulphonyl ester of formula (V) or (Va) respectively:



5

wherein n is as defined for the compound of formula (I) or (Ia), and R¹ is selected from C₁₋₆ alkyl (for example, methyl), C₁₋₆ perfluoroalkyl (for example, trifluoromethyl), aryl (for example, phenyl), tolyl (for example, *para*-tolyl), perfluoroaryl (for example, perfluorophenyl), and perfluorotolyl (for example, perfluoro *para*-tolyl). Thus, for example a [¹⁸F]fluorohaloalkyl compound of formula (Ia) may be converted to a [¹⁸F]fluoroalkyltosylate of formula (Va) such as [¹⁸F]fluoromethyltosylate. Fluoroalkylsulphonyl esters of formulae (V) and (Va) are also useful as fluoroalkylating agents.

15 Conversion of a compound of formula (I) or (Ia) to a compound of formula (V) or (Va) respectively, may be effected by reaction with the appropriate sulphonic acid of formula R¹SO₂OH or a salt thereof, such as a silver salt. Depending on the particular compound to be prepared, this conversion may be performed in solution phase, or in gaseous phase, for example by methods analogous to those described by Iwata *et al*, Applied Radiation and Isotopes, 57 (2002), 347-352.

The resulting compound of formula (I) or (Ia), or a corresponding compound of formula (V) or (Va) as described above, may be used in the preparation of a fluoroalkyl ligand or radiotracer, for example a [¹⁸F]fluoroalkylated radioligand or [¹⁸F]-radiotracer suitable for use in a PET study. Examples of [¹⁸F]fluoroalkylated radioligands and [¹⁸F]-radiotracers which may be prepared using the compounds of formula (Ia) or (Va) include 2-(1,1-dicyanopropen-2-yl)-6-(2-[¹⁸F]-fluoroC₁₋₆alkyl)-methylamino)naphthalene (for example, 2-(1,1-dicyanopropen-2-yl)-6-(2-[¹⁸F]-fluoroethyl)-methylamino)naphthalene, FDDNP), 3-(2'-[¹⁸F]fluoroC₁₋₆alkyl)spiperone (for example 3-(2'-[¹⁸F]fluoroethyl)spiperone), [¹⁸F][2-fluoroC₁₋₆alkoxy-5-(5-trifluoromethyl-tetrazol-1-yl)-benzyl]-([2S,3S]-2-phenyl-piperidin-3-yl)-amine (for

example, [^{18}F][2-fluoromethoxy-5-(5-trifluoromethyl-tetrazol-1-yl)-benzyl]-([2S,3S]-2-phenyl-piperidin-3-yl)-amine), 2-beta-carbomethoxy-3-beta-(4-iodophenyl)-8-(3-[^{18}F]fluoroC₁₋₆alkyl)-nortropine (for example, 2-beta-carbomethoxy-3-beta-(4-iodophenyl)-8-(3-[^{18}F]fluoropropyl)-nortropine, [^{18}F]fluoroC₁₋₆alkylflumazenil (for example, [^{18}F]fluoroethylflumazenil), [^{18}F]fluoroC₁₋₆alkyl-choline (for example, [^{18}F]fluoromethyl-choline or [^{18}F]fluoroethyl-choline), O-2[^{18}F]fluoroalkyl tyrosine (for example O-2[^{18}F]fluoroethyl tyrosine or O-2[^{18}F]fluoropropyl tyrosine), and 1-amino-3-[^{18}F]-fluoroalkylcyclobutane-1-carboxylic acid (for example, 1-amino-3-[^{18}F]-fluoromethylcyclobutane-1-carboxylic acid, (FMACBC)). Other
10 [^{18}F]fluoroalkylated radioligands and [^{18}F]-radiotracers which may be prepared using the compounds of formula (Ia) or (Va) include [^{18}F]-benzyl derivatives.

In the compounds of formulae (I), (Ia), (II), and (IIa), n is preferably 1, 2, or 3 such that the fluorohaloalkane prepared in the process is a fluorohalomethane,
15 fluorohaloethane, or fluorohalopropane.


Throughout the specification, the term "halo" means fluoro, chloro, iodo, or bromo.

In the compounds of formulae (I), (Ia), and (III), X is halo, and is preferably bromo
20 or iodo.

In the compounds of formula (III), Y is halo, preferably bromo or iodo, and is preferably the same as X, such that the compound of formula (III) is preferably Br₂ or I₂.
25

In the compounds of formula (II) and (IIa), R', R'', and R''' are suitably selected from C₁₋₆alkyl and C₁₋₆haloalkyl, more suitably C₁₋₄alkyl and C₁₋₄haloalkyl, for example methyl, ethyl, propyl, and isopropyl, typically methyl.


30 Where R'' is the group:



the "Solid Support" may be any suitable material which is insoluble in any solvents to be used in the process but to which the "Linker" and/or compound of formula (II) or (IIa) can be covalently bound. Examples of suitable solid support include
 5 polymers such as polystyrene (which may be block grafted, for example, with polyethylene glycol), polyacrylamide, and polypropylene or glass or silicon suitably coated with such a polymer. The solid support may be in the form of small discrete particles such as beads or pins, or as a coating on the inner surface of a cartridge or on a microfabricated vessel; and

10 the "Linker" may be any suitable organic group which serves to space the reactive site sufficiently from the solid support structure so as to maximise reactivity. Suitably, the Linker comprises an organic group of from 1 to 12 carbon atoms and from 0 to 6 heteroatoms selected from oxygen, nitrogen, and sulphur. Examples
 15 of such linkers are well known to those skilled in the art of solid-phase chemistry, but include phenyl/(C₁₋₆alkyl) and phenyl.

Compounds of formula (II) or (IIa) may be prepared from the corresponding compound of formula (IV):



wherein n, R', R'', and R''' are as defined for the compound of formula (II) or (IIa) and L is a leaving group;

30 by reaction with a source of F⁻, preferably ¹⁸F⁻, suitably an alkali metal fluoride salt such as Na¹⁸F, K¹⁸F, or Cs¹⁸F, tetraalkylammonium ¹⁸F fluoride, or tetraalkylphosphonium ¹⁸F fluoride.;

in the presence of a phase transfer catalyst, suitably 18-crown-6 or a cryptand such as Kryptofix 2.2.2., Kryptofix 2.2.2B., Kryptofix 2.2.1. (all available from Aldrich). The reaction may be performed in a suitable solvent such as acetonitrile and at elevated temperature, suitably 50°C to 100°C.

5


The leaving group, L, in the compound of formula (IV) is suitably a sulphonyl ester group i.e. $-\text{OSO}_2\text{R}^2$ wherein R^2 is selected from C_{1-6} alkyl (for example, methyl), C_{1-6} perfluoroalkyl (for example, trifluoromethyl), aryl (for example, phenyl), tolyl (for example, *para*-tolyl), perfluoroaryl (for example, perfluorophenyl), and

10

perfluorotolyl (for example, perfluoro *para*-tolyl).

Certain of the compounds of formula (IV) are novel, and therefore according to a further aspect of the invention there is provided a compound of formula (IV):


15



20

wherein n is an integer of from 1 to 6;

R' , R'' , and R''' are independently selected from C_{1-6} alkyl and C_{1-6} haloalkyl; and R'' may alternatively be the group:



25

L is a group $-\text{OSO}_2\text{R}^2$ wherein R^2 is selected from C_{1-6} alkyl, C_{1-6} perfluoroalkyl, aryl, perfluoroaryl, and perfluorotolyl;

provided that:

(a) when R'' is C_{1-6} alkyl or C_{1-6} haloalkyl, n is not 1; and

(b) when R'' is C_{1-6} alkyl or C_{1-6} haloalkyl and n is 3, L is not $-\text{OSO}_2\text{CH}_3$ or

30

$-\text{OSO}_2(\text{para-methyl})\text{phenyl}$.

Compounds of formula (IV) are either commercially available (for example, from

Aldrich), or a readily prepared from commercially available starting materials using methods available to the person skilled in the art. In one suitable method, the compound of formula (IV) is prepared by reaction of the corresponding azide with the appropriate sulphonic acid or a salt thereof, for example using methods
5 analogous to those described in Al-Busafi *et al*, Tetrahedron Letters, 39, 12 (1998).

The invention will now be illustrated by way of the following Example.

10 Example

Preparation of [^{18}F]fluorobromomethane

Trimethylsilylmethyl trifluoromethanesulphonate (Aldrich) (5mg) in acetonitrile (1ml) was added to fully dried ^{18}F /Kryptofix 2.2.2 complex prepared by standard
15 methods, for example as described in Hammacher *et al*, J. Nuclear Medicine, 27, 235-8 (1986). The mixture was heated at 75° C for 5 minutes. Tetrabutylammonium fluoride (16mg) in acetonitrile (0.5ml) and bromine (8mg) in methanol (0.5ml) were added to the reaction mixture. The reaction vessel was then sealed and heated at 110°C for 3 to 4 minutes.

20

[^{18}F]fluorobromomethane produced was then distilled from the vessel at the same temperature. The distillate containing [^{18}F]fluorobromomethane was passed under a stream of helium through a temperature controlled GC column (7.8 x 80 mm) packed with silica gel (70 to 270 mesh, Aldrich). The output from the GC column
25 was examined by a radioactive detector and the fraction with a retention time identical to that of authentic bromofluoromethane was directed to a cooled trapping vial containing a suitable solvent. Suitable solvents include acetonitrile, N,N-dimethylformamide, dimethylsulphoxide, tetrahydrofuran, acetone, acetic acid, and chlorobenzene. Other fractions were vented to waste. The overall
30 radiochemical yield for [^{18}F]fluorobromomethane from [^{18}F]fluoride was 55-70% and the total time for the preparation was approximately 45 minutes from the end

SEP-02 10:47
F20214

FROM-amersham group patents

+01494 543877

T-826 P.015/020 F-832


of radionuclide production.

Claims


1. A process for preparation of a fluorohaloalkane of formula (I)



wherein X is halo and n is an integer of from 1 to 6; which comprises:
reaction of the corresponding organosilicon compound of formula (II):



wherein n is as defined for the compound of formula (I); and
R', R'', and R''' are independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl; and
R'' may alternatively be the group:



with a compound of formula (III):




wherein X is as defined for the compound of formula (I) and Y is halo.

2. A process according to claim 1 for preparation of a [¹⁸F]fluorohaloalkane of formula (Ia)



wherein X is halo and n is an integer of from 1 to 6; which comprises:


reaction of the corresponding organosilicon compound of formula (IIa):



wherein n is as defined for the compound of formula (Ia); and

R', R'', and R''' are independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl; and

R'' may alternatively be the group:



with a compound of formula (III):




wherein X is as defined for the compound of formula (Ia) and Y is halo.

3. A process according to claim 1 or 2 which comprises the further step:

(i) isolation of the compound of formula (I) or (Ia); and/or

(ii) conversion of the compound of formula (I) or (Ia) to a corresponding fluoroalkylsulphonyl ester of formula (V) or (Va) respectively:



wherein n is as defined for the compound of formula (I) or (Ia), and R' is selected from C₁₋₆ alkyl, C₁₋₆ perfluoroalkyl, aryl, tolyl, perfluoroaryl, and perfluorotolyl.

4. A process according to any one of claims 1 to 3 which comprises the further step:

(i) use of the resulting compound of formula (I) or (Ia) in the preparation of a

fluoroalkyl ligand or radiotracer, such as a [^{18}F]fluoroalkylated radioligand or [^{18}F]-radiotracer.


- 5 5. A process according to claim 4 wherein the radioligand or radiotracer prepared is selected from:

2-(1,1-dicyanopropen-2-yl)-6-(2-[^{18}F]-fluoro C_{1-6} alkyl)-methyldamino)naphthalene,
3-(2'-[^{18}F]fluoro C_{1-6} alkyl)sipiperone,
[^{18}F][2-fluoro C_{1-6} alkoxy-5-(5-trifluoromethyl-tetrazol-1-yl)-benzyl]-([2S,3S]-2-phenyl-
piperidin-3-yl)-amine,
10 2-beta-carbomethoxy-3-beta-(4-iodophenyl)-8-(3-[^{18}F]fluoro C_{1-6} alkyl)-nortropane,
[^{18}F]fluoro C_{1-6} alkylflumazenil, and
[^{18}F]fluoro C_{1-6} alkyl-choline.

- 15 6. A process according to claim 4 or 5 wherein the [^{18}F]fluoroalkylated radioligand prepared is selected from:

2-(1,1-dicyanopropen-2-yl)-6-(2-[^{18}F]-fluoroethyl)-methyldamino)naphthalene,
3-(2'-[^{18}F]fluoroethyl)sipiperone,
[^{18}F][2-fluoromethoxy-5-(5-trifluoromethyl-tetrazol-1-yl)-benzyl]-([2S,3S]-2-phenyl-
piperidin-3-yl)-amine),
20 2-beta-carbomethoxy-3-beta-(4-iodophenyl)-8-(3-[^{18}F]fluoropropyl)-nortropane,
[^{18}F]fluoroethylflumazenil),
[^{18}F]fluoromethyl-choline, and
[^{18}F]fluoroethyl-choline).

- 25 7. A process for the preparation of a compound of formula (II) or (IIa) as defined in claim 1 or 2 which comprises reaction of a compound of formula (IV):




wherein n, R', R'', and R''' are as defined for the compound of formula (II) or (IIa), and L is a leaving group;

with a source of F⁻, preferably ¹⁸F⁻ in the presence of a phase transfer catalyst.

5


8. A compound of formula (II):




wherein n is an integer of from 1 to 6; and

R', R'', and R''' are independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl; and

15 R'' may alternatively be the group:




9. A compound of formula (IIa):



wherein n is an integer of from 1 to 6; and


R', R'', and R''' are independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl; and

R'' may alternatively be the group:




10. A compound of formula (IV):

5



10 wherein n is an integer of from 1 to 6;

R', R'', and R''' are independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl; and R'' may alternatively be the group:



15 L is a group -OSO₂R² wherein R² is selected from C₁₋₆ alkyl, C₁₋₆ perfluoroalkyl, aryl, perfluoroaryl, and perfluorotolyl; provided that:


(a) when R'' is C₁₋₆ alkyl or C₁₋₆ haloalkyl, n is not 1; and

(b) when R'' is C₁₋₆ alkyl or C₁₋₆ haloalkyl and n is 3, L is not -OSO₂CH₃ or -OSO₂(*para*-methyl)phenyl.

20


10. A compound of formula (IV):

5



10 wherein n is an integer of from 1 to 6;

R', R'', and R''' are independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl; and R'' may alternatively be the group:



15 L is a group -OSO₂R² wherein R² is selected from C₁₋₆ alkyl, C₁₋₆ perfluoroalkyl, aryl, perfluoroaryl, and perfluorotolyl; provided that:

(a) when R'' is C₁₋₆ alkyl or C₁₋₆ haloalkyl, n is not 1; and

(b) when R'' is C₁₋₆ alkyl or C₁₋₆ haloalkyl and n is 3, L is not -OSO₂CH₃ or -OSO₂(*para*-methyl)phenyl.

20

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.